Overview
Identification of a bacterial signature in the blood or stool that may be associated with acute rejection in patients treated with Nulojix during their first year of transplant.
Description
Gut microbiota as well as the signature of the 16S plasma bacterial DNA and bacterial metabolites of patients on the date of transplantation and during the first year after transplantation will be analyzed. The phenotype of the patients' T lymphocytes will be analyzed at the same time. These data will be correlated with the occurrence of acute cell rejection during the first year of transplantation
Eligibility
Inclusion Criteria:
- Patients called for a kidney transplant
- Induction therapy with Simulect, maintenance therapy with Nulojix, mycophenolate acid and steroids
- Patient having signed the informed consent
Exclusion Criteria:
- Multiple grafts combined or sequential
- Induction therapy with polyclonal antibodies
- HIV or active viral infection such as hepatitis B or C
- Active bacterial infection
- Pregnancy or breastfeeding at time of inclusion
- Patient unable to express their consent